Risks include immune-related pneumonitis, hepatitis, colitis, hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, type 1 diabetes mellitus, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, meningoencephalitis, pancreatitis, myocarditis and infusion-related reactions.
All patients receiving treatment with atezolizumab must be given a Patient Alert Card by their healthcare professional to educate them about the symptoms of immune-related adverse reactions.